LINC01362: A Potential Drug Target and Biomarker (G103283057)

Target Name: LINC01362

NCBI ID: G103283057

LINC01362

Other Name(s): Long intergenic non-protein coding RNA 1362 | long intergenic non-protein coding RNA 1362

LINC01362: A Potential Drug Target and Biomarker

Introduction

LINC01362 is a long intergenic non-protein coding RNA (lncRNA) molecule that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in a variety of tissues and cells, including the brain, heart , and liver. LINC01362 has been shown to play a role in the regulation of gene expression and has been associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Discovery of LINC01362

LINC01362 was first identified using RNA sequencing (RNA-seq) technology. RNA-seq is a high-throughput sequencing technology that allows researchers to identify and quantify RNA molecules in a sample. The LINC01362 gene was identified by RNA-seq analysis of brain RNA samples from the H reflex, which is the primary motor cortex in the brain.

Expression of LINC01362

LINC01362 is a highly expressed gene in a variety of tissues and cells, including the brain, heart, and liver. It is expressed at levels of up to 100 picograms per milliliter (pg/mL) in brain RNA samples, and has been shown to be expressed in other tissues as well. LINC01362 has been shown to be involved in the regulation of gene expression, and is thought to play a role in the development and progression of a number of diseases.

Drug Target Potential

The potential drug target for LINC01362 is based on its role in the regulation of gene expression and its expression in a variety of tissues. LINC01362 has been shown to play a role in the regulation of brain development and function, and is thought to be involved in the development of neurodegenerative diseases. Additionally, LINC01362 has been shown to be involved in the regulation of immune function, and is thought to play a role in the development of autoimmune disorders.

Biomarker Potential

LINC01362 has also been identified as a potential biomarker for a number of diseases. For example, LINC01362 has been shown to be expressed in brain tissue from patients with Alzheimer's disease, a neurodegenerative disorder. Additionally, LINC01362 has been shown to be expressed in heart tissue from patients with heart failure, a condition that is often treated with immunosuppressive drugs.

Conclusion

LINC01362 is a long intergenic non-protein coding RNA molecule that has been identified as a potential drug target and biomarker. Its expression has been shown in a variety of tissues and cells, including the brain, heart, and liver, and is thought to play a role in the regulation of gene expression and the development and progression of a number of diseases. Further research is needed to fully understand the potential of LINC01362 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1362

The "LINC01362 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01362 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets